Letters to the editor

American Journal of Psychiatry

Volumn 174, Issue 7, 2017, Pages 695-696

  Wilkinson, Samuel T ^a   Toprak, Mesut ^a   Turner, Mason S ^a   Levine, Steven P ^a   Katz, Rachel B ^a   Sanacora, Gerard ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; ANTIDEPRESSANT AGENT; TRANQUILIZER;

BIPOLAR DISORDER; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; HEART RATE; HUMAN; INSURANCE; LETTER; MAJOR DEPRESSION; MENTAL DISEASE; OFF LABEL DRUG USE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REIMBURSEMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; DEPRESSION; HEALTH CARE SURVEY;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER; HEALTH CARE SURVEYS; HUMANS; KETAMINE; OFF-LABEL USE; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

EID: 85021745005     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2017.17020239     Document Type: Letter

References (5)

1. Newport DJ, Carpenter LL, McDonald WM, et al.: Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015; 172:950-966
2. McGirr A, Berlim MT, Bond DJ, et al.: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 2015; 45:693-704
3. Sassano-Higgins S, Baron D, Juarez G, et al.: A review of ketamine abuse and diversion. Depress Anxiety 2016; 33:718-727
4. Morgan CJ, Muetzelfeldt L, Curran HV: Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2010; 105:121-133
5. Sanacora G, Heimer H, Hartman D, et al.: Balancing the promiseand risks of ketamine treatment for mood disorders. Neuropsychopharmacology 2017; 42:1179-1181